Global Non-Human Genomics Market Overview (2024 – 2030)

As of 2023, the Global Non-Human Genomics Market held a value of USD 10.69 billion, with a forecasted escalation to USD 28.25 billion by 2030. Over the analysis period of 2024 to 2030, the market anticipates a steady growth rate of 14.9% annually.

Industry Insights

The realm of non-human genetics focuses on engineering organisms with optimal traits. Through strategic breeding, traits can be selected to suit specific conditions or enhance resistance to diseases in non-human species. For instance, a genetically engineered cow might yield higher milk quantities while displaying resilience to prevalent bovine ailments such as bovine respiratory disease complex and clostridial disease, there by bolstering the overall profitability for cattle breeders. This facet of non-human genetics has garnered widespread acclaim, poised to propel the industry forward.

Moreover, an uptrend in educating the populace about non-human genetic testing is foreseen to further industry advancement. Noteworthy initiatives include the Veterinary Genetics Laboratory (VGL) at the UC Davis School of Veterinary Medicine, which unveiled an upgraded website and novel assays for the veterinary community in June 2020. Additionally, Embark Veterinary, Inc. rolled out its DNA test tailored for purebred canines in October 2021. This kit furnishes purebred owners with exclusive health insights, aiding veterinarians in crafting diagnostic, monitoring, and treatment strategies. Such initiatives are poised to amplify the utilization of genetic testing in non-human healthcare, thereby propelling industry growth.

The escalating deployment of advanced genetic technologies for large-scale production and enhanced breed quality is expected to be another growth driver. Consequently, the non-human genetics market is anticipated to witness substantial expansion throughout the forecast period. Conversely, a dearth of proficient experts for conducting genetics-related procedures in veterinary research might impede market expansion during the forecast horizon.

Impact of COVID-19 on the Industry

The COVID-19 pandemic is poised to exert a significant impact on the non-human genetics market. A study report published in Frontiers in Veterinary Science in September 2020 revealed the closure of numerous meat processing plants during the pandemic, notably in the United States. This led to a strain on the poultry and pig sectors, with a consequent decline in the daily slaughtering of livestock and cattle, thereby augmenting the population of non-humans on farms. In response, cattle producers were advised to moderate their breeding practices to curb the surge in farm non-humans. This trend potentially fueled increased genetic testing among non-humans on farms to mitigate the proliferation of non-human populations, thereby stimulating market expansion.

Market Drivers

The non-human genomics market is poised for growth as the emphasis intensifies on identifying superior disease-resistant breeds.

Researchers within the non-human genetics domain have unearthed genetic attributes that enhance non-human health, growth, and nutritional absorption capacities. These genetic strides augment output while mitigating environmental impacts. Globally, livestock and non-human species ensure food security and provide livelihoods for approximately one billion individuals, constituting roughly 40% of global agricultural output. Consequently, delving into non-human genetics to identify and cultivate disease-resistant breeds assumes paramount significance in the face of escalating populations. Moreover, the COVID-19 pandemic, originating in Wuhan and subsequently spreading worldwide, has claimed millions of lives, underscoring the necessity for safe and nutritious dietary practices. Hence, non-human genetics has emerged as a pivotal component within agriculture, including the breeding of non-human species.

The non-human genomics market stands to benefit from the burgeoning poultry farming sector catering to meat and dairy products.

Valued at over USD 1.4 billion in 2021, the poultry industry has witnessed a substantial uptick in demand for premium foods such as eggs, meat, and milk as compared to plant-based alternatives. Evolving consumption patterns, coupled with population growth and urbanization, have bolstered the demand within the chicken farming domain. Given the persistent and escalating demand for poultry non-human products, the overall market value is slated for continual augmentation throughout the projected timeframe.

Market Restraints

A scarcity of proficient professionals has emerged as a hindrance within the non-human genomics sector.

Pharmacogenomics, diagnostics, and toxicogenomics represent just a fraction of the applications reliant on genetic data. However, the analysis of the copious amounts of data generated within genomics research poses a significant challenge. While technological advancements have facilitated the provision of analyses via the instruments utilized, the interpretation remains subject to the reader's discretion. Given the complexities involved and the imperative for profound expertise in genomics, recruiting adept specialists to evaluate and interpret genome sequencing outcomes is imperative. Yet, owing to the paucity of qualified individuals, numerous end-users encounter challenges in processing genetic data effectively.

Global Non-Human Genomics Market - By Application

• Gene Expression
• Non-Human Breeding
• Genetic Trait Testing
• Genetic Disease Testing

The realm of non-human genetics delves into the study of heredity and genetic diversity among both domestic and wild non-human species. This domain encompasses investigations into gene expression, non-human breeding practices, and observable genetic traits solely dependent on inheritance, such as fur color, physique, facial structure, among others. DNA examinations, genetic trait assessments, and diagnostics for genetic diseases are all conducted within the sphere of non-human genetics. The projected growth of the non-human genetics market during the forecast period can be attributed to the escalating demand, heightened consumption of non-human proteins, and the surge in urban populations worldwide, all of which contribute to the increased demand for meat products.

Global Non-Human Genomics Market - By Technology

• Sequencing
• PCR
• Nucleic Acid Extraction and Purification
• Microarray
• Other Technologies

The Genomics Market segments its technological landscape into Sequencing, PCR, Nucleic Acid Extraction and Purification, Microarray, and Other Technologies. In 2021, the sequencing segment claimed the lion's share of revenue in the entirety of the Non-Human Genomics market. The attributes of sequencing technologies, such as their ultra-high throughput, scalability, and rapidity, empower researchers to undertake a diverse array of tasks, spanning from non-human breeding programs to applications in agriculture and human genomics.

Global Non-Human Genomics Market - By Geography & Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Leading the charge in the non-human genetics industry is North America, owing to its substantial players and the burgeoning demand for non-human proteins. Additionally, the increasing adoption of cutting-edge non-human genetics technologies and the well-established livestock sector are set to amplify the market's growth trajectory in this region.

The Asia Pacific market is poised to exhibit the most rapid growth during the forecast period. Factors such as the robust livestock industry, burgeoning porcine sector, escalating per capita incomes, augmented expenditure on non-human care, and a growing familiarity with technologically advanced non-human genetic products and services are all propelling the market's expansion in this region.

Global Non-Human Genomics Market - By Companies

1. Neogen Corporation (US)
2. Genus (UK)
3. URUS (US)
4. EW Group (Germany)
5. GroupeGrimaud (France)
6. CRV Holding (Netherlands)
7. TopigsNorsvin (Netherlands)
8. Zoetis (US)
9. Envigo (US)
10. Hendix Genetics (Netherlands)
11. Non-human Genetics (US)

Noteworthy Developments in the Global Non-Human Genomics Market:

Business Partnership:

In January 2021, Genus ABS collaborated with The Bair Ranch to demonstrate the impact of a cow-calf management system utilizing sex-skewed semen and terminal genetics.

Business Partnership:

In February 2020, Neogen collaborated with Gencove, a genetic testing company, to develop the next generation of non-human genomic tests.

Business Partnership:

In October 2020, Solidaridad and Hendrix Genetics joined forces to supply sustainable poultry in Mozambique and Zambia, Africa.